Continuity Biosciences erhält Fördermittel in Höhe von 9,6 Millionen US-Dollar zur Weiterentwicklung eines extrem langwirksamen Implantats zur HIV-Prävention

Summary

Continuity Biosciences received $9.6 million in funding to develop a long-acting subcutaneous implant for HIV prevention that delivers medication over multiple years after single implantation, with the goal of advancing toward an IND application and first clinical trials.